Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease

  • Konstantinos Petidis1,
  • Stella Douma1,
  • Michael Doumas1Email author,
  • Ilias Basagiannis1,
  • Konstantinos Vogiatzis1 and
  • Chrysanthos Zamboulis1
BMC Cardiovascular Disorders20088:11

https://doi.org/10.1186/1471-2261-8-11

Received: 29 November 2007

Accepted: 27 May 2008

Published: 27 May 2008

Abstract

Background

Acute vigorous exercise, associated with increased release of plasma catecholamines, transiently increases the risk of primary cardiac arrest. We tested the effect of acute submaximal exercise on vasoactive substances and their combined result on platelet function.

Methods

Healthy volunteers, hypertensive patients and patients with coronary artery disease (CAD) performed a modified treadmill exercise test. We determined plasma catecholamines, thromboxane A2, prostacyclin, endothelin-1 and platelet aggregation induced by adenosine diphosphate (ADP) and collagen at rest and during exercise.

Results

Our results during exercise showed a) platelet activation (increased thromboxane B2, TXB2), b) increased prostacyclin release from endothelium and c) decreased platelet aggregation in all groups, significantly more in healthy volunteers than in patients with CAD (with hypertensives lying in between these two groups).

Conclusion

Despite the pronounced activation of Sympathetic Nervous System (SNS) and increased TXB2 levels during acute exercise platelet aggregation decreases, possibly to counterbalance the prothrombotic state. Since this effect seems to be mediated by the normal endothelium (through prostacyclin and nitric oxide), in conditions characterized by endothelial dysfunction (hypertension, CAD) reduced platelet aggregation is attenuated, thus posing such patients in increased risk for thrombotic complications.

Background

Platelet aggregation and thrombosis play a central role in the pathogenesis of atherosclerosis, since platelet aggregates and thrombus formation has been found in the coronary arteries at sites of plaque rupture [1]. Platelets, upon their activation, further stimulate thrombus formation and recruit additional platelets by releasing thromboxane A2 (TXA2), adenosine diphosphate (ADP), and cytokines, which produce and promote surface thrombin generation and release vasoconstrictor substances [2]. Arterial hypertension, apart from being a major risk factor for atherosclerotic coronary artery disease, is characterized by an increased thrombotic tendency (the thrombotic paradox of hypertension or 'Birmingham paradox') with evidence of platelet activation, hypercoagulation and endothelial dysfunction [3]. Platelet dysfunction has attired attention as a potential cause of increased cardiovascular morbidity and mortality in essential hypertension [4]. All the above suggest the importance of platelet function in coronary artery disease and hypertension.

Platelet function is regulated by several factors that exhibit opposing effects, and the dynamic balance between prothrombotic and anti-antithrombotic factors determines health or thrombosis. Platelet activation is modulated by the function of normal endothelium that exerts a protective antithrombotic effect through the production of nitric oxide (NO) and prostacyclin (PGI2), substances that cause vasodilatation and inhibit platelet aggregation [2]. Endothelial dysfunction leads to nitric oxide (NO) deficiency which has been implicated in the underlying pathobiology of many of these disorders (NO insufficiency states) [5]. Moreover, endothelin-1 (ET-1, a potent vasoconscrictive substance released by the endothelium) and plasma catecholamines play a major role in the pathogenesis of acute ischemic events, and stimulate platelet aggregation, thus exerting prothrombotic actions.

In contrast to regular physical exercise that beneficially affects cardiovascular mortality [6], acute vigorous exercise that is characteristically accompanied by sympathetic nervous system (SNS) activation may trigger the occurrence of acute ischemic events [7]. Furthermore, epidemiological studies show that acute ischemic events exhibit a circadian rhythm coinciding with increased activity of the SNS and increased platelet aggregation during early morning hours [8]. SNS activation and the subsequent rise of plasma catecholamines result in increased platelet aggregation (possibly by activating platelet α2-adrenergic receptors), thus offering a possible explanation for the association between SNS activation and acute ischemic events [9].

Although several lines of evidence elucidate the function of each one of these vasoactive substances (catecholamines, TXA2, prostacyclin, and ET-1) in patients with coronary artery disease, their dynamic interaction remains largely unclarified. The aim of our study was to investigate platelet aggregation during acute submaximal exercise (representing SNS activation) in patients with coronary artery disease and hypertension compared to normal volunteers. Furthermore, we aimed at clarifying the potential contribution of vasoactive substances (such as catecholamines, thromboxane A2, prostacyclin and ET-1) on platelet aggregation by the simultaneous determination of these factors during acute exercise.

Methods

Study population

Our study population consisted of 60 subjects divided in three groups. Group A consisted of 18 healthy volunteers. They had never experienced signs or symptoms of coronary artery disease, their blood pressure was within normal levels, and they had no other risk factors for atherosclerosis (diabetes mellitus, hypercholesterolemia, obesity, smoking), and no positive family history of hypertension or coronary artery disease.

Group B consisted of 26 patients with essential hypertension (BP > 140/90 mmHg) according to current guidelines (JNC-7 and ESH/ESC). Secondary hypertension was excluded by clinical and, if appropriate, laboratory examination. All patients had recently diagnosed mild or moderate hypertension, confirmed in consecutive visits, and had never used antihypertensive drugs. Hypertensive patients with other cardiovascular risk factors beyond hypertension were excluded.

Group C consisted of 16 patients with known coronary artery disease that were in stable condition for at least three months. All patients were not on antiplatelet medication due to gastrointestinal problems.

Thus, we included three clearly discrete populations (completely healthy individuals without any cardiovascular risk factor, pure hypertensives without additional risk factors, and patients with overt coronary artery disease) in order to avoid potential confounding factors that affect platelet aggregation. The various number of subjects in each group is ought to the difficulties observed in performing study protocol.

Overall 144 subjects were screened and 78 of them were eligible for and agreed to participate in the study. Sixty-six patients were excluded from the study because they had concomitant conditions, such as diabetes mellitus or impaired glucose tolerance (21 patients), hyperlipidaemia (16 patients), smoking (18 subjects), extreme obesity (9 subjects), or positive family history for coronary artery disease or hypertension (10 subjects). The study protocol was very strict and laborious, and several difficulties had to be overtaken; thus, full compliance with protocol procedures was achieved in only 60 out of 78 individuals participating in the study. Specifically, blood sampling during treadmill exercise at all time points was not successful in 8 subjects, platelet aggregation could not be determined in 5 subjects due to technical difficulties, and the simultaneous determination of all vasoactive substances at each time point was not possible in 5 patients due to several technical factors. There were no statistically significant differences in baseline characteristics between the subjects excluded and the subjects participating in the study.

All individuals were sedentary and were not exercising on a regular basis. All subjects gave informed consent and the procedures followed were in accordance with institutional guidelines. The study was approved by the Hospital Ethics Committee and was in accordance with the principles of the Helsinki declaration.

Study protocol

All medications in the CAD group were stopped for at least one week. The use of aspirin, non-steroid anti-inflammatory drugs or other drugs that interfere with platelet function was prohibited for two weeks.

Blood pressure was measured using a mercury sphygmomanometer, following standard methodology. Three blood pressure recordings were obtained consecutively, and blood pressure was determined as the mean of the second and the third recording. Systolic blood pressure was defined at the point of appearance of the sounds (Korotkoff phase I), and diastolic blood pressure at the point of disappearance of the sounds (Korotkoff phase V).

A treadmill exercise test (Studio 350/4, Kardiolin, Quinton) was performed (modified protocol by Bruce) for 15 minutes with blood pressure and ECG monitoring. All subjects completed the exercise test with no symptoms or ECG signs of myocardial ischemia.

All tests were performed in the morning (8 am). With the patient in the supine position an intravenous indwelling catheter (18G) was inserted and normal saline (0.9%) was infused at a rate of 1 ml/min during the test. Blood was drawn with the ''two syringe" method. Samples were considered suitable for examination if blood flowed freely in the syringe. In total 4 blood samples were drawn. The first with the patient in the supine position just before the treadmill exercise (45 minutes after the placement of the intravenous catheter), the second sample was drawn after the completion of the first stage of the exercise test (9 min), the third sample at the end of the exercise (15 min) and the fourth in the recovery period with the subject in the supine position for 10 min.

Methods

Platelet aggregation was determined by nephelometry (method by Born). Blood was collected in tubes containing sodium citrate (0.11 M) in 9:1 ratio and centrifuged at 150 × g for 5 min. The resulting platelet-rich (PRP) plasma was kept at room temperature for use within 1 h. The rest of the blood was centrifuged at 1500 × g for 15 min and platelet-poor plasma (PPP) was prepared. Platelet counts were adjusted in each sample with the addition of homologous PPP to 250 ± 50 × 109/L. Platelet aggregation was determined with a four-channel aggregometer (PAP-4 Bio/Data). Platelet aggregation was induced by 50 μl of collagen and 50 μl of ADP to the final concentration of 10 μg/ml of collagen and 1 μM ADP. The aggregometer was adjusted before each experiment so that PRP permitted no light transmittance and the PPP permitted 100% light transmittance. Aggregation was expressed as the maximal percent change in light transmission from baseline, using PPP as a 100% and PRP as 0% reference of aggregation at the end of the recording time. Aggregation curves were recorded for 4 min.

Samples for plasma catecholamine (noradrenaline-NA and adrenaline-ADR) determination were collected in prechiled tubes containing heparin as anticoagulant. Catecholamines were measured with the use of High Performance Liquid Chromatography with Electrochemical Detector (HPLC-ECD).

Samples for plasma ET-1 determination were collected in tubes containing tripotassium ethylenediamine tetra-acetate (K3EDTA). Plasma ET-1 concentrations were determined by radioimmunoassay (Nichols Institute Diagnostics, San Juan Capistrano, CA), after solid-phase extraction on C14 columns, evaporation in vacuum-centrifuge, and reconstruction of the solid remainder.

Plasma prostacyclin is highly unstable so we measured the stable product 6-Keto-PGF1a with a radioimmunoassay (DRG Diagnostics). Plasma Thromboxane A2 is also unstable, so we measured the stable metabolite TXB2 by radioimmunoassay (DRG Diagnostics).

We also determined the ratio of 6-keto-prostaglandin-F1a to thromboxane B2 as an index of the balance between antiaggregatory Prostacyclin and pro-aggregatory Thromboxane A2.

Statistical analysis

Analysis was performed using the Statistical Package for Social Sciences (SPSS) 11,5 for Windows (SPSS Inc., Chicago, IL, USA). Results are presented as mean ± standard deviation (mean ± SD). Statistical analyses were carried out using the Independent samples t test and the Mann Whitney U test to compare proportions between 2 different groups, and the 2-tailed paired Student's test and the Wilcoxon Signed Rank Test to compare proportions of the same group in different instants. Values of p <0.05 were considered statistically significant.

Results

The baseline characteristics of the three groups are presented in Table 1. Normal volunteers were younger, leaner and had lower blood pressure than hypertensives and patients with coronary artery disease.
Table 1

Baseline characteristics of patients and healthy volunteers

 

Healthy volunteers n = 18

Hypertensives n = 26

CAD patients n = 16

Male/Female

15/3

22/4

13/3

Age (y)

33.9 ± 6.2

38.1 ± 6 *

40.9 ± 3.9 *

BMI kg/m2

23.54 ± 2.66

28.35 ± 2.57 *

29.07 ± 4.26 *

SBP mmHg

119.1 ± 8

143.2 ± 14.7 *

138.3 ± 21.9 *

DBP mmHg

79.9 ± 4.8

100.9 ± 4 *

91.4 ± 10.1 *

Heart Rate (/min)

72.7 ± 14.4

82.2 ± 11.9 *

76.4 ± 9.9

* p < 0.05 compared to healthy volunteers

CAD: coronary artery disease

Systolic blood pressure increased significantly in all three groups during treadmill exercise, while diastolic remained unchanged in patients with coronary artery disease or hypertension and fell, though not significantly, in healthy individuals. Blood pressure at all stages remained higher in the patients with coronary artery disease and hypertension (groups A and B) than in the healthy individuals (Figure 1). The Double Product was determined in all patients at the peak of exercise with no significant differences between the three groups (Table 2). Heart rate at the end of exercise as percentage of the maximum heart rate (predicted by an age based formula; maximum heart rate = 220-age) was determined and there were no significant differences between the three groups (Table 2).
Table 2

Characteristics of patients and healthy volunteers during exercise

 

Healthy volunteers n = 18

Hypertensives n = 26

CAD patients n = 16

Double Product mmHgxHR/minx10-3

26.2 ± 4

28.3 ± 5.4

26.2 ± 4.4

Heart Rate (beats/min)

72.7 ± 14.4

82.2 ± 11.9 *

76.4 ± 9.9

Peak Heart Rate (beats/min)

163.3 ± 14.6

158 ± 17.2

148.3.4 ± 15.7*

Percentage of maximum HR

85%

85.7%

82.8%

* p < 0.05 compared to healthy volunteers in all other parameters no significant differences were found between the three groups

CAD: coronary artery disease

Figure 1

Blood Pressure during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C).

* p<0.05 vs baseline, †p<0.05 vs healthy volunteers.

Plasma catecholamines increased significantly (p < 0.01) in all groups during exercise. Plasma noradrenaline at rest was higher in hypertensive patients (p < 0.01) and patients with coronary artery disease (p < 0.05) compared to healthy individuals. At exercise peak plasma noradrenaline increased about 10-fold, and hypertensives had higher noradrenaline levels than normal subjects (p < 0.01) and coronary patients (p = non significant, Figure 2A). Plasma adrenaline levels showed a similar fluctuation. At rest, hypertensive patients had higher plasma adrenaline levels but the difference was not significant. Plasma adrenaline increased during exercise in all three groups, and at exercise peak was higher in hypertensive individuals compared to healthy subjects (p < 0.01) and patients with coronary artery disease (p = non significant, Figure 2B).
Figure 2

A. Noradrenaline levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). B. Adrenaline levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C).

* p<0.05 vs baseline, **p<0.01vs baseline, †p<0.05 vs healthy volunteers, ††p<0.01 vs healthy volunteers.

The 6-keto-prostaglandin-F1a levels increased significantly (p < 0.05) during exercise in all three groups. Patients with coronary artery disease had lower plasma levels of 6-keto-prostaglandin-F1a compared to subjects from the other two groups and the difference was significant only at the peak of exercise compared with healthy volunteers (p < 0.05, Figure 3A).
Figure 3

A. 6-keto-Prostaglandin F1a levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). B. Thromboxane B2 levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). C. 6-keto-Prostaglandin F1a /Thromboxane B2 (PGI2/TXA2) ratio during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). D. Endothelin-1 levels during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C).

* p<0.05 vs baseline, **p<0.01vs baseline, †p<0.05 vs healthy volunteers, ††p<0.01 vs healthy volunteers.

Plasma TXB2 levels showed a significant increase during exercise in all three groups (p < 0.05), reaching their peak at maximum exercise. There was a trend towards higher levels at the end of exercise in patients with coronary artery disease, but there were no significant differences between the three groups (Figure 3B). Plasma TXB2 levels remained elevated compared to baseline after 10 min of rest.

The ratio of 6-keto-prostaglandin-F1a to thromboxane B2 decreased during exercise in all groups, but the decrease was statistically significant only for the CAD group (p = 0.01). There was no significant difference between the three groups at rest but at the peak of exercise patients with CAD had lower 6-keto-prostaglandin-F1a/thromboxane B2 ratio compared with healthy volunteers that almost reached statistical significance (p = 0.053) (Figure 3C). A negative correlation between the PGI2/TXB2 ratio and platelet aggregation at the end of exercise test with collagen (p < 0.05) and ADP (p = 0.07) was found in the group with CAD compared with controls, indicating that endothelial dysfunction (reduced ratio PGI2/TXB2) contributes to increased platelet aggregation in CAD patients.

Plasma ET-1 levels were higher at baseline in patients with coronary artery disease compared to healthy volunteers (p < 0.05), while during exercise ET-1 increased significantly (p < 0.05) only in hypertensive patients (Figure 3D).

Platelet aggregation decreased significantly during exercise (p < 0.05) in all groups with the use of ADP and collagen as inducing agents. At exercise peak, normal volunteers showed significantly greater inhibition of plasma aggregation when compared with hypertensives (p < 0.05) and patients with coronary artery disease (p < 0.05) with the use of both ADP and collagen (Figure 4A and 4B). After 10 min of rest platelet aggregation remained reduced in healthy volunteers compared to baseline (p < 0.05), while in hypertensives and patients with CAD increased and was higher than in healthy volunteers (p < 0.05).
Figure 4

A. Platelet aggregation (with ADP) changes during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C). B. Platelet aggregation (with collagen) changes during exercise in healthy volunteers (A), hypertensives (B) and patients with CAD (C).

* p<0.05 vs baseline, **p<0.01 vs baseline, †p<0.05 vs healthy volunteers, ††p<0.01 vs healthy volunteers.

Discussion

Thrombotic events represent the most common and important complication of atherosclerotic disease. The clarification of pathophysiologic mechanisms underlying the thrombotic process seems of utmost importance for the prevention of such events and the improved management of these patients. Our study findings indicate that patients with coronary artery disease exhibit a thrombotic tendency compared to healthy subjects during exercise (increased platelet aggregation compared to healthy individuals), while hypertensive patients are lying in between these two groups.

Exercise may induce platelet activation in vivo and enhanced platelet reactivity in vitro, but results concerning exercise-induced platelet aggregation are far from unanimous. Much controversy exists regarding platelet function during SNS activation; studies examining the results of physical and mental stress on platelet aggregation in hypertensives and in patients with ischemic heart disease have shown conflicting results [911]. Platelet responses to exercise depend on several factors, such as exercise intensity, the exercise protocol used, and physical fitness. Moreover, measurements of platelet reactivity either in vitro or ex vivo (aggregability assays) or in vivo (platelet secretory products, mainly beta thromboglobulin and platelet factor 4) are associated with considerable methodologic difficulties and thus may account for the discrepancies of results reported in the literature.

Our findings of decreased platelet aggregation during exercise despite the increase in plasma catecholamines seem paradoxical. Increased shear-stress in states of increased SNS activity results in increased platelet aggregation, probably mediated by the action of adrenaline, as its infusion results in increased platelet aggregation in normotensives and hypertensives [1214]. There is evidence that the increased platelet aggregation in the early morning hours is due to increased sensitivity to the action of adrenaline [15]. The stimulatory effect of epinephrine on platelet functions has been linked to activation of α2-adrenoceptor in the membrane of the platelets, since the effect can be blocked by yohimbine, a specific antagonist of α2-adrenoceptor [16]; moreover, catecholamines during strenuous exercise have been shown to enhance platelet activation, facilitate the ability of ADP-activated fibrinogen receptors, promote fibrinogen binding to platelet receptors, and more importantly increase the number of α2-adrenoceptors despite a decrease in their affinity [17]. Thus, the decreased platelet aggregation found in our study might be explained by two hypotheses: a) either noradrenaline that increases much more than adrenaline (five fold more) during exercise exerts different effects on platelet aggregation, or b) other factors induced by physical exercise counter-regulate the negative effects of adrenaline on platelet aggregation.

Regarding the first hypothesis, experimental studies have shown increased intra-arterial thrombosis during adrenaline infusion but decreased thrombosis during noradrenaline infusion [18]. In addition, prolonged exposure of platelets to increased adrenaline levels results in decreased aggregation to adrenaline, probably due to adrenergic receptor downregulation [19]. There is also evidence that β2 adrenergic receptor stimulation causes inhibition of adhesion and aggregation in platelets through increased NOS activity in platelets [20]. β2 adrenergic receptor-mediated inhibition of adhesion and aggregation in platelets may partially offset the proaggregatory effects of α2 adrenergic receptor stimulation in response to the endogenous catecholamines (noradrenaline and adrenaline).

Regarding the second scenario, noradrenaline has been reported to be able to stimulate endothelial cells to release prostacyclin and nitric oxide, both of which are known to be potent inhibitors of platelet aggregation [21]. In addition, the increased blood flow during exercise causes increased shear stress and vasodilatation through the production of NO and PGI2[22]. The increased prostacyclin production, plasma NO metabolites and platelet cGMP may suppress platelet reactivity [2325]. All our patients exhibited increased PGI2 production during exercise, a potent inhibitor of platelet aggregation. The difference was significant between healthy volunteers and patients with coronary artery disease.

Accumulating evidence suggests that platelets of hypertensive patients show signs of activation25 and an increased tendency to aggregate [27]. Hypertensive patients showed higher urinary excretion rate of 11-dehydro-TXB2 compared with normotensive controls [28]. Furthermore, exercise is associated with increased TXA2 production [2931]. On the other hand, products of platelet activation (serotonin, TXA2, ADP) directly increase platelet aggregation. At the same time, these agents act on endothelial cells and cause further release of prostacyclin and NO and inhibit platelet aggregation2. During exercise TXB2 production was increased in all groups, more in patients with coronary artery disease and less in healthy volunteers but the difference was not statistically significant. The balance between PGI2 and TXA2, as expressed by the ratio of 6-keto-prostaglandin-F1a to thromboxane B2 was changed in favour of the prothrombotic TXA2 in patients with CAD, that exhibit the higher degree of endothelial dysfunction.

Increased endothelin-1 levels during exercise may contribute to the pathogenesis of acute myocardial infarction that sometimes follows vigorous physical exercise. Even small increments of ET-1 may facilitate vasoconstrictive responses of coronary vessels to other stimuli. Although ET-1 generation de novo requires several hours there is evidence that ET-1 is stored within internal storage vesicles of endothelial cells, and its secretion is a rapid process with the formation and transit time of a vesicle to the plasma taking approximately 10 min. This could explain the abnormal ET-1 synthesis and release during exercise in our patients with hypertension [32]. The fact that only hypertensive patients exhibited an increase in ET-1 is probably explained by the fact that known mechanisms of ET-1 secretion, as increased SNS activity, pressure and shear stress [33] were higher during exercise in hypertensive patients. Experimental data concerning ET-1 effects on platelet function are contradictory showing decreased [34], increased [35] or unchanged [36] platelet aggregation. The increased levels of ET-1 in hypertensives and patients with coronary artery disease are consistent with the endothelial dysfunction present in these patients and the role of ET-1 in cardiovascular disease.

Endothelial dysfunction is characterized by a reduction in prostacyclin and NO, probably resulting in a thrombogenic vascular environment that allows thrombus formation induced by exposure of highly thrombogenic substances from ruptured or erosive plaques. Even though the differences were not statistically significant, healthy individuals had higher PGI2 and lower TXA2 levels, while patients with coronary heart disease had lower PGI2 and higher TXA2. The negative correlation between the PGI2/TXA2 ratio and platelet aggregation in CAD patients indicates that endothelial dysfunction contributes to the thrombotic tendency in these patients.

A major limitation of our study is that normotensives are younger and leaner than the other two groups, and despite their abstinence of regular exercise this may have influenced favourably their response to exercise. Although evidence regarding the relationship between obesity and platelet aggregation are contradictory [37], data from the Northwick study suggest that obesity (body weight or body mass index) is not associated with platelet aggregation in a large sample of about 1000 subjects [38]. Another important limitation of our study is the lack of oxygen consumption estimation during exercise in order to evaluate exercise intensity; however, the use of the double product and the percentage of maximum heart rate achieved at exercise peak as indirect indices of oxygen consumption (revealing a comparable exercise intensity in the three groups) overcomes this limitation. Finally, in our study, NO metabolites and platelet aggregation after adrenaline induction were not determined; we believe that the evaluation of these parameters, in a clinical setting similar to ours, will significantly contribute to the clarification of the mechanisms underlying thrombosis in CAD, thus representing an excellent idea for further research in this area.

Conclusion

In summary, platelet aggregation was inhibited during exercise in healthy individuals, hypertensives and patients with coronary artery disease. This inhibition of platelet aggregation probably represents a protective endothelial mechanism through the production of PGI2 and NO. Endothelial dysfunction is probably responsible for the smaller inhibition of platelet aggregation during exercise in patients with coronary artery disease and hypertensives compared to healthy subjects. The negative correlation between the PGI2/TXA2 ratio and platelet aggregation in CAD patients indicates that endothelial dysfunction contributes to the thrombotic tendency in these patients. Other causes as defective intraplatelet NO production or resistance of platelets to the action of NO cannot be refuted.

Abbreviations

CAD: 

coronary artery disease

TXB2

thromboxane B2

SNS: 

Sympathetic Nervous System

ADP: 

adenosine diphosphate

TXA2

thromboxane A2

NO: 

nitric oxide

PGI2

prostacyclin

ET-1: 

endothelin-1

PRP: 

platelet-rich plasma

PPP: 

platelet-poor plasma

NA: 

noradrenaline

ADR: 

adrenaline

HPLC-ECD: 

High Performance Liquid Chromatography with Electrochemical Detector

Declarations

Acknowledgements

The authors would like to thank Fani Hatzivassiliou for her technical assistance in performing the platelet aggregation tests.

Authors’ Affiliations

(1)
2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki

References

  1. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J: Atherosclerotic Vascular Disease Conference Writing Group III: Pathophysiology. Circulation. 2004, 109: 2617-2625. 10.1161/01.CIR.0000128520.37674.EF.View ArticlePubMedGoogle Scholar
  2. Ware JA, Heistad DD: Platelet-Endothelium interactions. N Engl J Med. 1993, 328: 628-635. 10.1056/NEJM199303043280907.View ArticlePubMedGoogle Scholar
  3. Lip GY: Hypertension and the prothrombotic state. J Hum Hypertens. 2000, 14: 687-690. 10.1038/sj.jhh.1001051.View ArticlePubMedGoogle Scholar
  4. Kjeldsen SE, Neubig RR, Weder AB, Zweifler AJ: The hypertension-coronary heart disease dilemma: the catecholamine-blood platelet connection. J Hypertens. 1989, 7: 851-860. 10.1097/00004872-198911000-00001.View ArticlePubMedGoogle Scholar
  5. Loscalzo J: Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001, 88: 756-762. 10.1161/hh0801.089861.View ArticlePubMedGoogle Scholar
  6. Paffenbarger RS, Hyde RT, Wing AL, Lee I-M, Jung DL, Kampert JB: The Association of Changes in Physical-Activity Level and Other Lifestyle Characteristics with Mortality among Men. N Engl J Med. 1993, 328: 538-545. 10.1056/NEJM199302253280804.View ArticlePubMedGoogle Scholar
  7. Siscovick DS, Weiss NS, Fletcher RH, Lasky T: The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984, 311: 874-877.View ArticlePubMedGoogle Scholar
  8. Tofler GH, Brezinski DA, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden death. N Engl J Med. 1987, 316: 1514-1518.View ArticlePubMedGoogle Scholar
  9. Hjemdahl P, Larsson PT, Wallén NH: Effects of stress and β-blockade on platelet function. Circulation. 1991, 84 (6 Suppl): VI44-61.PubMedGoogle Scholar
  10. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD: Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 1993, 88: 1502-1511.View ArticlePubMedGoogle Scholar
  11. Larsson PT, Wallen NH, Hjemdahl P: Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994, 89: 1951-1957.View ArticlePubMedGoogle Scholar
  12. Goto S, Ikeda Y, Murata M, Handa M: Epinephrine Augments von Willebrand Factor-Dependent Shear-Induced Platelet Aggregation. Circulation. 1992, 86: 1859-1863.View ArticlePubMedGoogle Scholar
  13. Hjemdahl P, Chronos NA, Wilson DJ, Bouloux P, Goodall AH: Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin. Arterioscler Thromb Vasc Biol. 1994, 14 (10): 77-84.View ArticleGoogle Scholar
  14. Douma S, Zamboulis Chr, Karagiannis A, Sinakos Z: The effects of Adrenaline infusion on serum thromboxane β2 and plasma β-thromboglobulin levels in hypertensives and normotensive subjects. Nouvelle Revue Francaise d'Hematologie. 1992, 34: 73-8.PubMedGoogle Scholar
  15. Mores N, Martire M, Pistritto G, Volpe AR, Menini E, Folli G, Cardillo C: Platelet alpha2-adrenoreceptors and diurnal changes of platelet aggregability in hypertensive patients. J Hypertens. 1994, 12: 939-945. 10.1097/00004872-199408000-00012.View ArticlePubMedGoogle Scholar
  16. Berlin I, Crespo-Laumonnier B, Cournot A, Landault C: The alpha-2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol Ther. 1991, 49: 362-369.View ArticlePubMedGoogle Scholar
  17. Wang JS, Cheng LJ: Effect of strenuous, acute exercise on α2-adrenergic agonist-potentiated platelet activation. Arterioscler Thromb Vasc Biol. 1999, 19 (6): 1559-1565.View ArticlePubMedGoogle Scholar
  18. Lin H, Young DB: Opposing effects of plasma epinephrine and norepinephrine on coronary thrombosis in vivo. Circulation. 1995, 91: 1135-1142.View ArticlePubMedGoogle Scholar
  19. Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S: Effect of circulating epinephrine on platelet function and hematocrit. Hypertension. 1995, 25: 1096-1105.View ArticlePubMedGoogle Scholar
  20. Queen LR, Xu B, Horinouchi K, Fisher I, Ferro A: β2-Adrenoceptors Activate Nitric Oxide Synthase in Human Platelets. Circulation Research. 2000, 87: 39-44.View ArticlePubMedGoogle Scholar
  21. Jones CJH, DeFily DV, Patterson JL, Chilian WM: Endothelium-dependent relaxation competes with α1- and α2-adrenergic constriction in the canine epicardial coronary microcirculation. Circulation. 1993, 87: 1264-1274.View ArticlePubMedGoogle Scholar
  22. Oates JA, Fitzgerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ: Clinical implications of prostaglandin and thromboxane A2 formation (I). N Engl J Med. 1988, 319: 689-698.View ArticlePubMedGoogle Scholar
  23. de Graaf JC, Banga JD, Moncada S, Palmer RMJ, de Groot PG, Sixma JJ: Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992, 85: 2284-2290.View ArticlePubMedGoogle Scholar
  24. Hambrecht R, Adams V, Erbs S, Linke A, Krankel N, Shu Y, Baither Y, Gielen S, Thiele H, Gummert JF, Mohr FW, Schuler G: Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase. Circulation. 2003, 107: 3152-3158. 10.1161/01.CIR.0000074229.93804.5C.View ArticlePubMedGoogle Scholar
  25. Wang J-S, Jen CJ, Chen H-I: Effects of chronic exercise and deconditioning on platelet function in women. J Appl Physiol. 1997, 83: 2080-2085.PubMedGoogle Scholar
  26. Nadar SK, Blann AD, Kamath S, Beevers DG, Gregory YH, Lip GYH: Platelet indexes in relation to target organ damage in high-risk hypertensive patients. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol. 2004, 44: 415-422. 10.1016/j.jacc.2004.03.067.View ArticlePubMedGoogle Scholar
  27. Blann AD, Nadar S, Lip GYH: Pharmacological Modulation of Platelet Function in Hypertension. Hypertension. 2003, 42: 1-10.1161/01.HYP.0000077901.84467.E1.View ArticlePubMedGoogle Scholar
  28. Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan M: Determinants of platelet activation in human essential hypertension. Hypertension. 2004, 43: 64-70. 10.1161/01.HYP.0000105109.44620.1B.View ArticlePubMedGoogle Scholar
  29. Todd MK, Goldfarb AH, Boyer BT: Effect of exercise intensity on 6-keto-PGF1 alpha, TXB2 and on 6-keto-PGF1 alpha/TXB2 ratios. Thromb Res. 1992, 65: 487-493. 10.1016/0049-3848(92)90200-T.View ArticlePubMedGoogle Scholar
  30. Lemne C, Vesterqvist O, Egberg N, Green K, Jogestrand T, de Faire U: Platelet activation and prostacyclin release in essential hypertension. Prostaglandins. 1992, 44 (3): 219-235. 10.1016/0090-6980(92)90015-L.View ArticlePubMedGoogle Scholar
  31. Piret A, Niset G, Depiesse E, Wyns W, Boeynaems JM, Poortmans J, Degre S: Increased platelet aggregability and prostacyclin biosynthesis induced by intense physical exercise. Thromb Res. 1990, 57: P685-695. 10.1016/0049-3848(90)90026-9.View ArticleGoogle Scholar
  32. Harrison VJ, Barnes K, Turner AJ, Wood E, Corder R, Vane JR: Identification of Endothelin 1 and Big Endothelin 1 in Secretory Vesicles Isolated from Bovine Aortic Endothelial Cells. PNAS. 1995, 92: 6344-6348. 10.1073/pnas.92.14.6344.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Haynes WG, Webb DJ: Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998, 16: 1081-1098. 10.1097/00004872-199816080-00001.View ArticlePubMedGoogle Scholar
  34. Pietraszek MH, Takada Y, Takada A: Endothelins inhibit serotonin-induced platelet aggregation via a mechanism involving protein kinase C. European journal of Pharmacology. 1992, 219: 289-293. 10.1016/0014-2999(92)90308-Q.View ArticlePubMedGoogle Scholar
  35. Liras A, Catalan RE, Martinez AM: Synergistic Effect of Endothelin-1 and Serotonin in Rabbit Platelets: Effect on Tyrosine Phosphorylation. Thrombosis Research. 2000, 100: 325-331. 10.1016/S0049-3848(00)00328-5.View ArticlePubMedGoogle Scholar
  36. Dockrell MEC, Walker BR, Noon JP, Graham C.M, Watt GCM, Brent C, Williams BC, Webb DJ: Platelet Aggregation in Young Men with Contrasting Predisposition to High Blood Pressure. Am J Hypertens. 1999, 12: 115-119. 10.1016/S0895-7061(98)00215-5.View ArticlePubMedGoogle Scholar
  37. Lee KW, Lip GYH: Effects of lifestyle on hemostasis, fibrinolysis and platelet reactivity. Arch Intern Med. 2003, 163: 2368-2392. 10.1001/archinte.163.19.2368.View ArticlePubMedGoogle Scholar
  38. Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ: Epidemiological characteristics of platelet aggregability. BMJ. 1985, 290: 428-32.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/8/11/prepub

Copyright

© Petidis et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement